Research programme: Fas receptor antagonists - ONL Therapeutics

Drug Profile

Research programme: Fas receptor antagonists - ONL Therapeutics

Alternative Names: Met12; ONL 1204; ONL101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ONL Therapeutics
  • Class Eye disorder therapies; Peptides; Small molecules
  • Mechanism of Action CD95 antigen inhibitors; Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal detachment
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration
  • No development reported Retinal detachment

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Retinal detachment in USA (Intravitreous, Injection)
  • 11 Feb 2016 ONL 1204 receives Orphan Drug status for Retinal detachment in USA
  • 15 Jun 2015 ONL Therapeutics plans a clinical trial for Retinal detachment in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top